60% ROIC
22% EPS growth
35% Net income margin
23 forward PE

$NVO is fairly valued at this price after the massive overreaction from CagriSema's trial resulting in a 22.7% weight loss rate instead of 25%... https://t.co/fnHrg8TCMd